Patent directory · USPTO A61K / A61P
Patents matching “mab”
86 pharma patents match "mab" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 86 pharmaceutical patents matching "mab" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11433025
Oil foamable carriers and formulations
granted -
US 11365246
Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases
granted -
US 11352432
Antibodies specifically binding to human IL-1R7
granted -
US 11229702
High concentration formulations of adalimumab
granted -
US 11219631
Foamable compositions, breakable foams and their uses
granted -
US 11197928
Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
granted -
US 11166906
Programmable pharmaceutical compositions for chrono drug release
granted -
US 11154494
Programmable pharmaceutical compositions for chrono drug release
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11098126
Anti-MET antibodies and uses thereof
granted -
US 11091561
HER-2 binding antibodies
granted -
US 11071780
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
granted -
US 11033491
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
granted -
US 10967063
Surfactant-free, water-free formable composition and breakable foams and their uses
granted -
US 10946101
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
granted -
US 10799585
Stable aqueous formulations of adalimumab
granted -
US 10786566
Stable aqueous formulations of adalimumab
granted -
US 10780163
Stable aqueous formulations of adalimumab
granted -
US 10772960
Stable aqueous formulations of adalimumab
granted -
US 10772959
Stable aqueous formulations of adalimumab
granted -
US 10772956
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted -
US 10722579
Stable aqueous formulations of adalimumab
granted -
US 10716852
Stable aqueous formulations of adalimumab
granted -
US 10716853
Stable aqueous formulations of adalimumab
granted